With dedicated project management and logistic teams, the central lab is fully integrated into ClinTrak – Medpace’s global decision support technology, which allows for the transfer of real time data to support clinical studies.
CROs have increasingly been turning to Singapore as a gateway to the region, with Covance, PPD and Parexel extending their operations to the Asian country.
The Medpace Singapore facilities have been equipped with identical instrumentation, and use the same reagent systems, calibration, QA process and SOPs as their counterparts in Cincinnati, Ohio; Leuven, Belgium; and Beijing, China. The lab will also provide routine safety, biomarker and reference methodologies identical to what is offered elsewhere.
The push into the Asia Pacific region comes nearly three months since Medpace was acquired by UK-based private equity firm Cinven for $915m. Cinven previously discussed the potential for growth in Asia for the CRO, which targets smaller to mid-market biotech, pharma and medical device companies.
The expansion also comes as Medpace will collaborate with NephroGenex on a Phase III study of a diabetic kidney disease treatment.
All Medpace laboratories are directly supervised by full-time doctoral level laboratory professionals including MDs and PhDs with board certification in Pathology/Laboratory Medicine. Each lab location also maintains accreditation by the College of American Pathologists (CAP), and NGSP Level 1 and CDC Lipid Standardization (LSP) Part III programs, which provide Medpace with the ability to deliver consistent, identical and highly standardized laboratory analysis.